A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Peptide p277 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DIA-AID; DIA-AID-1
- Sponsors Andromeda Biotech
- 01 May 2014 Results published in the Diabetes Care.
- 25 Jun 2013 Preliminary results from the open-label extension study presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 19 Oct 2012 Planned number of patients changed from 450 to 500.